newsfilter
← Latest News
Business Wire·

MorphoSys AG Reports First Quarter 2023 Financial Results

– Monjuvi® U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023 – Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline